Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment
European Journal of Haematology · 2026-05 · 116 (5) · 577-584
DOI: 10.1111/ejh.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 14.01.2026. Verfasst von Rintu Sharma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Center, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Renal Dialysis, Renal Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Methods
We retrospectively analyzed outcomes in NDMM patients presenting with severe dialysis‐requiring RI from 01/2010 to 12/2022.
Results
Seventy patients were identified; all receiving novel agent‐based induction (bortezomib‐based 96%; lenalidomide‐based 3%)—73% ( n = 51) underwent ASCT. Thirty‐three (48%) patients became dialysis independent; early achievement of VGPR in < 4.4 months from treatment initiation was identified as the only factor predicting renal recovery and dialysis withdrawal on univariate analysis (Hazard ratio [HR] of 4.172; p‐ value = 0.0014). At median follow‐up of 39 months, the median overall survival (OS) of dialysis‐requiring NDMM patients was 98.3 months with 2‐ and 5‐year OS rates of 84% and 67%, respectively; 2‐ and 5‐year progression‐free survival (PFS) rates were 66.9% and 43.7%, respectively. On multivariable analysis, low LDH at diagnosis (HR: 1.003, p = 0.0092), undergoing ASCT (HR: 0.213; p ‐value = 0.0016), and dialysis independence (HR: 0.311; p ‐value = 0.0112) independently predicted improved OS.
Conclusions
Early VGPR and hemodialysis independence translated to improved survival, providing a benchmark for future comparison as anti‐CD38 monoclonal antibodies enter first line therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Princess Margaret Cancer Center, Toronto, ON, Canada.
- Biostatistics, University Health Network, Toronto, ON, Canada.
- University of Auckland, Auckland, New Zealand.
ORCID-Profile: Rintu Sharma, Christine Chen
Zitieren
APA
Sharma, R., Atenafu, E. G., Masih-Khan, E., Vohra, H., Bhella, S., Chen, C., Kukreti, V., Lancman, G., Prica, A., Stewart, A. K., Tiedemann, R., Trudel, S., Yang, C., & Reece, D. (2026). Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment. European Journal of Haematology, 116(5), 577-584. https://doi.org/10.1111/ejh.70116
Vancouver
Sharma R, Atenafu EG, Masih-Khan E, Vohra H, Bhella S, Chen C, et al. Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment. European Journal of Haematology. 2026;116(5):577-584. doi:10.1111/ejh.70116
BibTeX
@article{Sharma2026,
author = {Sharma, Rintu and Atenafu, Eshetu G and Masih-Khan, Esther and Vohra, Harjot and Bhella, Sita and Chen, Christine and Kukreti, Vishal and Lancman, Guido and Prica, Anca and Stewart, A Keith and Tiedemann, Rodger and Trudel, Suzanne and Yang, Chloe and Reece, Donna},
title = {Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {5},
pages = {577--584},
doi = {10.1111/ejh.70116}
}
EUVIMED